Financial Counselors Inc. reduced its stake in Eli Lilly and Company (
) by 1.0% during the 1st quarter, as reported by the company in its latest disclosure to the Securities and Exchange Commission. The institutional investor held 54,216 shares of the company's stock after offloading 552 shares during the quarter. The holdings of Financial Counselors Inc. in Eli Lilly and Company were valued at $18,619,000 at the conclusion of the most recent quarter.
Numerous other institutional investors have also recently traded shares of the company. Fairfield Bush & CO. acquired a new position in Eli Lilly and Company shares during the first quarter, valued at approximately $107,000. Roundview Capital LLC increased its stake in Eli Lilly and Company shares by 2.6% in the first quarter. After buying an additional 53 shares last quarter, Roundview Capital LLC now holds 2,056 shares of the company's stock, valued at $589,000. Merit Financial Group LLC purchased a new position in Eli Lilly and Company shares in the first quarter, valued at approximately $210,000. NewEdge Advisors LLC increased its stake in Eli Lilly and Company shares by 9.9% in the first quarter. After buying an additional 4,774 shares last quarter, NewEdge Advisors LLC now holds 53,052 shares of the company's stock, valued at $15,193,000. Lastly, Barometer Capital Management Inc. acquired a new position in Eli Lilly and Company shares in the first quarter, valued at approximately $561,000. Institutional investors and hedge funds own 87.25% of the company's stock.
In other news, CAO Donald A. Zakrowski sold 600 shares of the company's stock in a transaction on Monday, May 15th. The shares were sold at an average price of $435.29, totaling $261,174.00. After the sale, the chief accounting officer now owns 5,978 shares of the company's stock, valued at roughly $2,602,163.62. The sale was disclosed in a legal filing with the SEC, which can be accessed at the SEC website. Also, EVP Patrik Jonsson sold 6,000 shares of the company's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $429.46, totaling $2,576,760.00. After the sale, the executive vice president now owns 36,941 shares of the company's stock, valued at $15,864,681.86. The disclosure for this sale can be found here. Over the last three months, insiders have sold 970,965 shares of company stock valued at $423,725,107. Corporate insiders own 0.13% of the company's stock.
Analysts from Wall Street Share Their Opinions
Several brokerages have recently given their opinions on LLY. Morgan Stanley increased their price target for Eli Lilly and Company from $551.00 to $560.00, giving the company an 'overweight' rating in a report released on Friday. Credit Suisse Group also raised their price target for Eli Lilly and Company from $420.00 to $490.00 in a report published on Thursday, May 4th. Berenberg Bank increased their price target for Eli Lilly and Company from $375.00 to $500.00 in a report issued on Tuesday, June 20th. HSBC initiated coverage on Eli Lilly and Company in a report on Friday, July 14th, issuing a 'buy' rating and a $560.00 price target for the stock. Lastly, BMO Capital Markets raised their price target for Eli Lilly and Company from $505.00 to $565.00 in a report on Tuesday, July 18th. One research analyst has given the stock a sell rating, two have given a hold rating, and fifteen have given a buy rating to the company. According to MarketBeat, the company has a 'Moderate Buy' average rating and an average price target of $458.36.
Trading Down 0.4%, Eli Lilly and Company
On Friday, NYSE LLY began trading at $462.04. The firm's current ratio stands at 1.30, its quick ratio at 1.02, and its debt-to-equity ratio at 1.67. The company's fifty-day simple moving average is $446.38, while its 200-day simple moving average is $386.55. Over the past year, Eli Lilly and Company's stock has fluctuated between a low of $296.32 and a high of $469.87. The company boasts a market capitalization of $438.60 billion, a P/E ratio of 73.46, a PEG ratio of 2.12, and a beta of 0.38.
The last time Eli Lilly and Company (
Access Free Report
) released its quarterly earnings data was on Thursday, April 27th. The firm announced a $1.62 earnings per share for the quarter, falling short of the consensus estimate of $1.73 by ($0.11). Eli Lilly and Company recorded a net margin of 20.54% and a return on equity of 61.42%. The firm's revenue for the quarter was $6.96 billion, slightly above the consensus estimate of $6.87 billion. In the same quarter of the previous year, the company reported $2.62 earnings per share. Eli Lilly and Company's revenue decreased by 10.9% on a year-over-year basis. Analysts, on average, forecast that Eli Lilly and Company will register 8.78 EPS for the current fiscal year.
Eli Lilly and Company Declares Dividend
The company also recently announced a quarterly dividend, set to be paid on Friday, September 8th. Those who are shareholders on record as of Tuesday, August 15th will receive a dividend of $1.13 per share. This equates to an annualized dividend of $4.52 and a yield of 0.98%. The ex-dividend date for this dividend is Monday, August 14th. The current dividend payout ratio (DPR) for Eli Lilly and Company stands at 71.86%.
Regarding Eli Lilly and Company
Eli Lilly and Company is a global entity that is involved in the discovery, development, and marketing of human pharmaceuticals. Its product range includes Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500, all of which are used for diabetes treatment. Additionally, it offers Jardiance, Trajenta, and Trulicity for the management of type 2 diabetes.
Interested in finding out which other hedge funds hold LLY?
Check out HoldingsChannel.com
for the most recent 13F filings and insider transactions for Eli Lilly and Company (
Get Daily News & Ratings for Eli Lilly and Company
- Provide your email address below to get a brief daily roundup of the most recent news and analysts' ratings for Eli Lilly and Company and associated companies with
MarketBeat.com's complimentary daily email newsletter.